Health Discovery (HDVY) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'HEALTH DISCOVERY CORP	'	'
Entity Central Index Key	'0001141788	'	'
Trading Symbol	'hdvy	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Common Stock, Shares Outstanding	'	252,557,310	'
Entity Public Float	'	'	$7,022,569
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$71,991	$171,424
Accounts Receivable	80	90
Investment in Available For Sale Securities (Note J)	724,000	1,716,160
Total Current Assets	796,071	1,887,674
Equipment, Less Accumulated Depreciation of $55,133 and $47,219	5,752	11,329
Other Assets	'	'
Patents, Less Accumulated Amortization of $2,519,290 and $2,256,570	1,466,504	1,729,224
Total Assets	2,268,327	3,628,227
Current Liabilities	'	'
Accounts Payable - Trade	326,267	139,790
Accrued Liabilities	2,500	55,500
Dividends Payable - S/T	308,724	'
Deferred Revenue	1,024,988	1,024,988
Total Current Liabilities	1,662,479	1,220,278
Long Term Liabilities	'	'
Deferred Revenue	191,628	1,216,616
Dividends Payable	'	455,546
Total Liabilities	1,854,107	2,892,440
Stockholders' Equity	'	'
Common Stock, No Par Value, 300,000,000 Shares Authorized 252,557,310 Shares Issued and Outstanding December 31, 2013 233,773,144 Shares Issued and Outstanding December 31, 2012	26,368,892	25,445,813
Accumulated Deficit	-26,792,574	-26,017,654
Total Stockholders' Equity	414,220	735,787
Total Liabilities and Stockholders' Equity	2,268,327	3,628,227
Series B Preferred Stock Convertible	'	'
Stockholders' Equity	'	'
Preferred Stock, Convertible	677,902	1,307,628
Series C Preferred Stock Convertible	'	'
Stockholders' Equity	'	'
Preferred Stock, Convertible	$160,000	'

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accumulated depreciation on equipment (in dollars)	55,133	47,219
Accumulated amortization on patents (in dollars)	2,519,290	2,256,570
Common Stock, no par value (in dollars per share)	'	'
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	252,557,310	233,773,144
Common Stock, shares outstanding	252,557,310	233,773,144
Series B Preferred Stock Convertible	'	'
Preferred Stock, shares authorized	20,625,000	20,625,000
Preferred Stock, shares issued	8,827,500	17,027,675
Preferred Stock, shares outstanding	8,827,500	17,027,675
Series C Preferred Stock Convertible	'	'
Preferred Stock, shares authorized	12,500,000	12,500,000
Preferred Stock, shares issued	2,000,000	'
Preferred Stock, shares outstanding	2,000,000	'

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:	'	'
Licensing & Development	$1,053,607	$1,585,517
Operating Expenses:	'	'
Amortization	262,719	262,719
Professional and Consulting Fees	714,701	698,676
Legal Fees	269,961	228,557
Research & Development Fees	115,934	127,648
Compensation	524,144	1,483,899
Other General and Administrative Expenses	418,221	621,266
Total Operating Expenses	2,305,680	3,422,765
Loss From Operations	-1,252,073	-1,837,248
Other Income (Expense)	'	'
Unrealized (Loss) / Gain on Fair Value of NGNM (Note J)	-288,600	726,600
Realized Gain on Fair Value of NGNM (Note J)	815,753	668,852
Interest Income	'	1,059
Settlement Expense (Note G)	-50,000	'
Total Other Income (Expense)	477,153	1,396,511
Net Loss	-774,920	-440,737
Preferred Stock Dividends	137,256	139,481
Loss Attributable to Common Shareholders	($912,176)	($580,218)
Weighted Average Outstanding Shares (in shares)	235,494,741	232,124,255
Loss Per Share (basic and diluted) (in dollars per share)	($0.00)	($0.00)

Statements_of_Changes_in_Stock

Statements of Changes in Stockholders' Equity (USD $)	Preferred Shares	Preferred Shares	Common Shares	Accumulated Deficit	Total
	Preferred Shares B	Preferred Shares C
Balance at Dec. 31, 2011	$1,307,628	'	$25,691,078	($25,576,917)	$1,421,789
Balance (in shares) at Dec. 31, 2011	17,340,175	'	231,299,810	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Series B Preferred Stock Exchanged for Common Stock	'	'	'	'	'
Series B Preferred Stock Exchanged for Common Stock (in shares)	'	'	'	'	'
Shares issued pursuant upon the exercise of options (in shares)	'	'	473,334	'	'
Stock options issued for Services	'	'	150,000	'	150,000
Stock issued for services (in shares)	'	'	2,000,000	'	'
Share-based Compensation and Expense	'	'	94,098	'	94,098
Series B Preferred Stock Special Dividend	'	'	-349,882	'	-349,882
Series B Preferred Stock Annual Dividend	'	'	-139,481	'	-139,481
Net Loss	'	'	'	-440,737	-440,737
Balance at Dec. 31, 2012	1,307,628	'	25,445,813	-26,017,654	735,787
Balance (in shares) at Dec. 31, 2012	17,340,175	'	233,773,144	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Series C Preferred Stock Issued	'	160,000	'	'	160,000
Series C Preferred Stock Issued (in shares)	'	2,000,000	'	'	'
Series B Preferred Stock Exchanged for Common Stock	-629,726	'	629,726	'	'
Series B Preferred Stock Exchanged for Common Stock (in shares)	-8,512,675	'	8,512,675	'	'
Stock options issued for Services	'	'	124,889	'	124,889
Share-based Compensation and Expense	'	'	30,855	'	30,855
Series B Preferred Stock Dividend Paid with Common Stock	'	'	274,865	'	274,865
Series B Preferred Stock Dividend Paid with Common Stock (in shares)	'	'	10,271,491	'	'
Series B Preferred Stock Annual Dividend	'	'	-137,256	'	-137,256
Net Loss	'	'	'	-774,920	-774,920
Balance at Dec. 31, 2013	$677,902	$160,000	$26,368,892	($26,792,574)	$414,220
Balance (in shares) at Dec. 31, 2013	8,827,500	2,000,000	252,557,310	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities	'	'
Net Loss	($774,920)	($440,737)
Adjustments to Reconcile Net Loss to Net Cash Used for Operating Activities:	'	'
Stock-based compensation	30,855	94,098
Common stock issued for services	124,889	150,000
Realized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J)	-815,753	-668,852
Unrealized Loss / (Gain) on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J)	288,600	-726,600
Decrease in Deferred Charges	'	44,764
Depreciation and Amortization	270,633	272,877
Increase in Accounts Receivable	10	307
Decrease in Deferred Revenue	-1,024,988	-535,060
Decrease in Prepaid Expenses and Other Assets	'	45,350
Increase (Decrease) Accounts Payable - Trade	186,476	-238,364
(Decrease) Increase in Accrued Liabilities	-53,000	34,000
Net Cash Used by Operating Activities	-1,767,198	-1,968,217
Cash Flows From Investing Activities:	'	'
Proceeds from Sale of Available for Sale Securities (Note J)	1,519,313	1,624,092
Purchase of Equipment	-2,336	-3,878
Net Cash Provided by Investing Activities	1,516,977	1,620,214
Cash Flows From Financing Activities:	'	'
Proceeds from Series C Preferred Stock Issuance	160,000	'
Dividends Paid	-9,212	-370,899
Net Cash Provided by (Used for) Financing Activities	150,788	-370,899
Net Decrease in Cash	-99,433	-718,902
Cash, at Beginning of Period	171,424	890,326
Cash, at End of Period	$71,991	$171,424

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Note A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	DESCRIPTION OF BUSINESS
	Health Discovery Corporation (the “Company”) is a biotechnology-oriented company that has acquired patents and has patent pending applications for certain machine learning tools, primarily pattern recognition techniques using advanced mathematical algorithms to analyze large amounts of data thereby uncovering patterns that might otherwise be undetectable.  Such machine learning tools are currently in use for diagnostics and drug discovery, but are also marketed for other applications.  The Company licenses the use of its patented protected technology and may provide services to develop specific learning tools under development agreements or to sell to third parties.
	USE OF ESTIMATES
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period.  Accordingly, actual results could differ from those estimates.  Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the recoverability of the patents.
	REVENUE RECOGNITION
	Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements.  These arrangements are generally governed by contracts that dictate responsibilities and payment terms.  The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled.  If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.
	CASH AND CASH EQUIVALENTS
	Cash and cash equivalents include cash and monies invested in overnight funds with financial institutions.
	ACCOUNTS RECEIVABLE
	Trade accounts receivable for licensing fees and development services are recorded at net contract value based upon the written agreement with the customer. In certain cases, accounts receivable may include royalties’ receivable from customers based upon those customers estimated sales of the products or diagnostic tests containing patented processes and technologies. The Company considers amounts past due based on the related terms of the agreement and reviews its exposure to amounts receivable based upon collection history and specific customer credit analysis.  The Company provides an allowance for doubtful amounts if collectability is no longer reasonably assured.  As of December 31, 2013 and 2012, all amounts receivable are considered fully collectable and no allowance for doubtful accounts was recorded.
	PROPERTY AND EQUIPMENT
	Property and equipment, which consists of office furniture, computer equipment and leasehold improvements, are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 10 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter.
	PATENTS
	Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued.  Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the capitalized costs to date in the period of abandonment or earlier if abandonment appears probable.  The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2013, the Company does not believe there has been any impairment of its intangible assets.
	INVESTMENTS
	The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies, but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies.
	INCOME TAXES
	The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled.
	In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such assets is made. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies.
	STOCK-BASED COMPENSATION
	Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
	Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model.  Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates.
	Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior.
	Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility.
	Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
	RESEARCH AND DEVELOPMENT EXPENSE
	The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. The R&D costs were $115,934 in 2013 and $127,648 in 2012.
	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company’s financial instruments consist of cash, accounts receivable, accounts payable and accrued expenses.  The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note J for discussion regarding the valuation of the Company’s investment in available for sale securities.
	NET LOSS PER SHARE
	Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss in all periods presented the calculation of diluted per share amounts would cause an anti-dilutive result and therefore is not presented. Potentially dilutive shares at December 31, 2013 and 2012 include options and warrants outstanding of 13,500,000 and 12,250,000, respectively.
	CONCENTRATIONS OF CREDIT RISK
	The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account.  From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC.  Management believes the risk of loss of cash balances in excess of the insured limit to be low.
	RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the FASB issued an amendment, which requires disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance is effective prospectively for annual and interim periods beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our financial results.

DEFERRED_REVENUE

DEFERRED REVENUE	12 Months Ended
	Dec. 31, 2013
Deferred Revenue Disclosure [Abstract]	'
DEFERRED REVENUE	'
	Note B – DEFERRED REVENUE
	Deferred revenue represents the unearned portion of payments received in advance for licensing or service agreements.
	The Company received $500,000 in cash in March 2010 in connection with a licensing agreement completed in the first quarter of 2010. Deferred revenue of $500,000 was recorded and recognized as income over the estimated remaining term of the underlying patents of approximately 8 years, subject to the terms of the license agreement. The licensing and development revenue recognized during the twelve month period ended December 31, 2012 includes $457,088 related to the acceleration of the revenue recognition from deferred revenue because of the termination of the Abbott and Quest contracts as noted in the following paragraph.
	The Company received $2,944,800 as a part of the NeoGenomics license agreement in January 2012. Deferred revenue of $2,944,800 was recorded and is being recognized as income over the three years of the term of the license agreement.
	The Company had total unearned revenue of $1,216,616 as of December 31, 2013. The long-term portion of unearned revenue represents the remaining term of the agreements or the remaining lives of the underlying patents, as appropriate, and ranges from one to seven years.
	The expected future annual recognition of revenue is as follows:
	2014	$	1,024,988
	2015		43,388
	2016		43,388
	2017		43,388
	2018		43,388
	Thereafter		18,076
	Total expected future annual amortization	$	1,216,616

PATENTS

PATENTS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
PATENTS	'
	Note C – PATENTS
	The Company has acquired a group of patents related to biotechnology and certain machine learning tools used for diagnostic and drug discovery.
	The cost and accumulated amortization for 2013 and 2012 are as follows:
		2013			2012
	Cost of Patents	$	3,985,794		$	3,985,794
	Accumulated Amortization		(2,519,290	)		(2,256,570	)
	Patents, Net of Amortization	$	1,466,504		$	1,729,224
	Amortization charged to operations for each of the years ended December 31, 2013 and 2012 was $262,719.  The weighted average remaining amortization period for patents at December 31, 2013 is 5.50 years.  Estimated amortization expense for the next five years is $260,603 per year.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
INVESTMENTS	'
	Note D – INVESTMENTS
	On March 27, 2007, the Company and an investment partner formed SVM Capital, LLC (“SVM Capital) as an equity investment for purposes of utilizing SVMs as a quantitative investment management technique.  The Company owns 45% of the membership interest and has significant influence with the operation of the entity but does not have control over the entity. The Company does not have any obligation to fund or provide support to SVM Capital.  Accordingly, the investment is accounted for using the equity method of accounting.  The Company’s initial investment was $5,000 and the license to use the SVM technology applied to financial markets.  The carrying value of this investment was zero as of December 31, 2013 and December 31, 2012.
	In August 2008, pursuant to a license agreement, as amended, we contributed a license to Smart Personalized Medicine, LLC (“SPM”) in return for a 20% equity interest.  SPM is a company founded by a former director to develop a breast cancer prognostic test using our SVM technology in collaboration with a prominent cancer research hospital. The only activity for this entity was the Quest license and development agreements of 2010 for which there was an allocation of 50% to HDC and 50% to the other partner. The Company does not have any contractual obligation to provide any funds to this venture. The net value of the investment was zero as of December 31, 2013 and December 31, 2012. The Company does not anticipate the relationship with SPM will generate any revenue.

LICENSE_FEES_EXPENSE_LUCENT_AG

LICENSE FEES EXPENSE - LUCENT AGREEMENT	12 Months Ended
	Dec. 31, 2013
License Fees Expense Lucent Agreement [Abstract]	'
LICENSE FEES EXPENSE - LUCENT AGREEMENT	'
	Note E – LICENSE FEES EXPENSE - LUCENT AGREEMENT
	Effective September 26, 2004, the Company was assigned a patent license agreement with Lucent Technologies GRL Corporation (“Lucent”).  The patent license agreement was associated with the patents acquired July 30, 2004. The Company agreed to pay royalty fees to Lucent in the amount of the greater of an annual fee of $10,000 or at the rate of five percent (5%) on each licensed product which is sold, leased, or put into use by the Company, until cumulative royalties equal $40,000 and at the rate of one percent (1%) subsequently.  The license granted will continue for the entire unexpired term of Lucent’s patents.  During 2013, the Company paid $10,536 in royalty fees to Lucent compared to $13,237 paid during 2012.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	Note F – INCOME TAXES
	The Company has incurred net losses since inception, and we have determined that it is more likely than not we will be unable to benefit in the future from the accumulated net operating loss.  Consequently, we have not recorded any U.S. federal or state income tax expense or benefit.  We have no recorded income tax provision or benefit for the fiscal years ending December 31, 2013 or 2012.
	The following items comprise the Company’s net deferred tax assets (liabilities) as of December 31, 2013 and 2012.
		2013			2012
	Net operating loss	$	7,682,814		$	6,979,391
	Deferred revenue		413,649			762,145
	Charitable contributions		510			1,088
	Depreciation and amortization		-			2,441
	Stock compensation		54,655			414,119
	Deferred tax asset		8,151,628			8,159,184
	Depreciation and amortization		(4,007	)		-
	Unrealized gain		(148,920	)		-
	Deferred tax liability		(152,927	)		-
	Net deferred tax asset		7,998,701			8,159,184
	Less valuation allowance		(7,998,701	)		(8,159,184	)
	Net deferred taxes	$	-		$	-
	As of December 31, 2013, an increase in the valuation allowance of $160,482 has been recorded for the deferred tax asset, as management has determined that it is more likely than not that the deferred tax asset will not be realized.
	Total income tax expense (benefit) differed from the amounts computed by applying the U.S. Federal statutory tax rates to pre-tax loss for the fiscal years ending December 31, 2013 and 2012 as follows:
	2013		2012
	Total expense (benefit) computed by:
	Applying the U.S. Federal statutory rate		(34.0	)%		(34.0	)%
	State income taxes, net of federal tax benefit		(3.0	)		(3.0	)
	Valuation allowance		37			37
	Effective tax rate (benefit)		-			-
	The Company has unused net operating loss carry-forwards of approximately $22.6 million that are available to offset future income taxes payable. The net operating losses will begin to expire in 2020.
	Based in its evaluation of tax positions, the Company has concluded that there are no significant uncertain tax positions requiring recognition in its financial statements.  The Company’s evaluation was performed for all tax years, which remain subject to examination and adjustment, by major tax jurisdictions as of December 31, 2013. The Company is generally no longer subject to U.S. federal, state, and local, or non-US income tax examinations for the years before 2010.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Legal Matters and Commitment [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	Note G – COMMITMENTS AND CONTINGENCIES
	Operating Lease
	We do not own any real property.  We lease 350 square feet of office space in Atlanta, Georgia, pursuant to a month-to-month lease dated April 1, 2013. We currently pay base rent in the amount of $600 per month. Our principal executive office is located at 4243 Dunwoody Club Drive, Suite 202, Atlanta, Georgia, and our telephone number is (678) 336-5300.  Our principal executive office is well maintained and suitable for the business conducted in this location.
	Settlements
	The previous Board of Directors negotiated a settlement agreement in July 2013 with Stephen Barnhill, the former Chairman and Chief Executive Officer of the Company.  Under the terms of the Settlement Agreement, (i) the Company paid $50,000 to, or for the benefit of, Mr. Barnhill and (ii) Mr. Barnhill executed a general release in favor of the Company, subject to any indemnification rights that Mr. Barnhill may have under any agreement, law, or insurance policy maintained by the Company. As a result, the Company recognized a settlement expense of $50,000 in 2013.
	Legal Issues
	On July 17, 2013, the Company received a Civil Investigative Demand (the “Demand”) from the Federal Trade Commission of the United States of America (the “FTC”) relating to the Company’s MelApp software application. In the Demand, the FTC has requested information relating to potentially unfair or deceptive acts or practices related to (i) false advertising and (ii) consumer privacy and data security, in violation of Trade Commission Act, 15 U.S.C. Sections 45 and 42. The Company has gathered the information and responded to the request by the FTC in accordance with the terms of the Demand. At this time, the Company is awaiting a response from the FTC regarding the Demand.  It would premature to estimate what the response will be from the FTC and the potential, if any, impact to the Company.
	The Company is subject to various claims primarily arising in the normal course of business.  Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

STOCK_COMPENSATION_AND_EQUITY_

STOCK COMPENSATION AND EQUITY BASED PAYMENTS	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
STOCK COMPENSATION AND EQUITY BASED PAYMENTS	'
	Note H – STOCK COMPENSATION AND EQUITY BASED PAYMENTS
	Information about options and warrants outstanding for 2013 and 2012 is summarized below:
	Number of Warrants and Options Issued	2013			Weighted Average		2012			Weighted Average
					Exercise Price					Exercise Price
	Outstanding beginning of year		12,250,000		$	0.1		30,291,667		$	0.16
	Granted		17,750,000		$	0.04		1,000,000		$	0.05
	Exercised		-		$	-		(473,334	)	$	0.07
	Forfeited		(8,500,000	)	$	0.12		(3,000,000	)	$	0.12
	Expired un-exercised		(8,000,000	)	$	0.08		(15,568,333	)	$	0.21
	Outstanding end of the year		13,500,000		$	0.05		12,250,000		$	0.1
	Exercisable December 31		4,750,000		$	0.04		11,000,000		$	0.11
	31-Dec-13
	Exercise Prices	Number			Weighted-		Number			Weighted
		Outstanding			Average		Exercisable			Average
					Remaining					Remaining
					Contractual					Contractual Life
					Life (years)					(years) of
										Exercisable
										Warrants
	$0.03		3,000,000			9.5		-			-
	$0.04		7,750,000			9.75		2,000,000			9.75
	$0.04		1,000,000			4		1,000,000			4
	$0.05		1,000,000			4		1,000,000			4
	$0.08		750,000			0.5		750,000			0.5
	Total		13,500,000					4,750,000
	As of December 31, 2013, there was approximately $193,940 of unrecognized cost related to stock option and warrant grants.  The cost is to be recognized over the remaining vesting periods that average approximately 2.5 years.  The weighted average remaining life of all outstanding warrants and options at December 31, 2013 are 9.5 years.  The aggregate intrinsic value of all options and warrants outstanding and exercisable as of December 31, 2013 was $636,237.
	Stock-based expense included in the 2013 net loss consisted of $155,744 in director’s option expenses and common stock issued for services. Specifically, director option expenses were $30,855 and common stock issued for service expenses related to employees and consultants were $124,889. These were lower than the director option expense of $94,098 and stock grant expenses for Mr. Norris and Mr. Barnhill of $150,000 in 2012.
	The following table reflects stock-based compensation and expense recorded in 2013 and 2012:
		2013			2012
	Director’s option expenses	$	30,855		$	94,098
	Common stock issued for services		124,889			150,000
	Net Increase	$	155,744		$	244,098
	On December 18, 2012, the Company entered into an employment contract with Mr. Norris. Under the terms of that employment agreement, Mr. Norris received a one-time bonus of 1,000,000 shares of the Company’s common stock.
	Also as a part of that employment agreement, Mr. Norris also was granted an option to purchase shares of the Company’s common stock. These options will be granted and vest according to the following schedule: (i) 1,000,000 options were granted on December 18, 2012 at an exercise price of $0.05 and vest during the six months following the grant date, plus the potential to earn additional options if certain anniversary dates and other milestones were met. None of those milestones were met and therefore not awarded.
	In connection with their appointment to the Board of Directors, on February 28, 2013, the Company granted to Mr. David Eckoff, Mr. Sumio “Sumi” Takeichi and Mr. John Norris each an option to purchase 1,500,000 shares of the Company’s common stock. The options vest over a three-year period, have an exercise price of $0.032, and expire on February 28, 2023.  The fair value of each option granted is $0.023 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.97%, an expected life of 5 years, and volatility of 96%.  All of these options were forfeited upon each of these individuals departure from the Board and are no longer in effect.
	As a part of his consulting agreement with the Company, Dr. Herbert Fritsche was awarded an option to purchase 1,000,000 shares of the Company’s common stock. The options vest immediately, have an exercise price of $0.04, and expire on February 1, 2018.  The fair value of each option granted is $0.029 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.91%, an expected life of 5 years, and volatility of 97%.  The value of these options is $29,454, and this amount was charged as an expense in the second quarter 2013.
	In connection with his appointment to the Board of Directors in May 2013, the Company granted to Mr. Norman Mineta an option to purchase 1,500,000 shares of the Company’s common stock. The options vest over a three-year period, have an exercise price of $0.048, and expire on May 10, 2023.  The fair value of each option granted is $0.035 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.91%, an expected life of 5 years, and volatility of 97%.  These options were forfeited upon Mr. Mineta’s departure from the Board and are no longer in effect.
	In connection with their election to the Board of Directors, on July 25, 2013, the Company granted to Mr. Henry Kaplan, Mr. Kevin Kowbel, and Mr. Eric Winger each an option to purchase 1,500,000 shares of the Company’s common stock. Upon his appointment to Interim Chief Executive Officer, Mr. Kowbel returned his options back to the Company. As a result, only the options for Messrs. Kaplan and Winger vest 250,000 shares every six months, have an exercise price of $0.027, and expire on July 25, 2023.  The fair value of each option granted is $0.020 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.91%, an expected life of 5 years, and volatility of 98%.  The aggregate computed value of these options is $60,124, and this amount will be charged as an expense over the three-year vesting period. There is no expense related to Mr. Kowbel as he returned all of the options granted to him back to the Company.
	In connection with his appointment to the Board of Directors in July 2013, on October 21, 2013, the Board of Directors of Health Discovery Corporation (the “Company”) granted to Mr. William F. Quirk, Jr. an option to purchase 1,500,000 shares of the Company’s common stock. This option grant is consistent with what has been granted to other board members. The options vest 250,000 shares every six months, have an exercise price of $0.036, and expire on October 21, 2023.
	Also, on October 21, 2013, the Company granted options to purchase 6,000,000 shares of the Company’s common stock to a group of employees and consultants in recognition of their efforts to lower the Company’s monthly expenditures and compensation and their continuing contributions to the Company.  The options vest over a three-year period, have an exercise price of $.036, and expire on October 21, 2023. Within the group of 6,000,000 options, the Company’s Vice President, Mark A. Moore, Ph.D., received an option to purchase 1,000,000 shares of the Company’s common stock and the Company’s Senior Vice President, Hong Zhang, Ph.D., received an option to purchase 750,000 shares of the Company’s common stock.  The non-cash charge of $203,931 for the fair value of these options will be recognized as an expense over the three-year vesting period.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	Note I - STOCKHOLDERS’ EQUITY
	Series B Preferred Stock
	During the first quarter of 2009 the Board of Directors authorized the designation of Series B Preferred Stock. The number of shares originally constituting the Series B Preferred Stock was 13,750,000; however, during the fourth quarter of 2009 the Board of Directors authorized the increase in the number of shares constituting the Series B Preferred Stock to 20,625,000. The Company sold to individual investors a total of 19,402,675 shares of Series B Preferred Stock for $1,490,015, net of associated expenses, in 2009.  The Series B Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.
	The Series B Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series B Preferred Stock will converted into Common Stock of the Company in the fourth quarter of 2014, which the fifth anniversary of the date of issuance.
	The Series B Preferred Stock has accrued dividends at the rate of 10% of the Series B Original Issue Price per year, which shall be satisfied by the fifth anniversary of the issuance of such shares of the Series B Preferred Stock (the “Original Issue Date”) by the Company’s issuance of the number of shares of Common Stock equal to such accrued dividends divided by the average closing price of the Company’s Common Stock as reported on the Over-the-Counter-Bulletin Board or other exchange on which the Company’s Common Stock trades during the prior ten business days or by the payment of cash, as the Company may determine in its sole discretion. Dividends have been accrued for the Series B Preferred Stock in the amount of $308,724 as of December 31, 2013 and $455,546 as of December 31, 2012. The Company plans to satisfy the accrued dividend for the Series B Preferred Stock in the fourth quarter of 2014.
	Subject to the limitations set forth in the Amended and Restated Articles of Amendment to Articles of Incorporation and applicable law, as long as the Series B Preferred Stock remain outstanding, the Company pay the holders of the Series B Preferred Stock a special dividend equal to 15% of Company Net Revenue collected beginning with the Original Issue Date and ending on the date the Series B Preferred Stock cease to be outstanding (the “Cash Bonus”).  Company Net Revenue will include, but not be limited to, revenue derived from development fees, license fees and royalties paid to the Company and revenue collected as a result of the sale of any asset of the Company or distributions from SVM Capital, LLC (each a “Revenue Contract”), reduced by the amount of any out-of-pocket costs or expenses that are directly related to obtaining, negotiating or documenting the Revenue Contracts and the performance of such Revenue Contracts, but shall not include the proceeds of any capital infusions from the exercise of outstanding options or warrants or as a result of any capital raise undertaken by the Company.  At any time following the Original Issue Date, the Company may satisfy the special dividend right in its entirety if the aggregate payments made to the Series B Holders are equal to that value which provides an internal annual rate of return of twenty percent (20%) on the Series B Preferred Stock.  The maximum Cash Bonus to be paid each year shall be the aggregate Series B Original Issue Price, and no amounts in excess of such amount shall accrue or carry-over to subsequent years.
	During the fourth quarter of 2012, the Company made payments to the Series B holders for the special dividend. Dividends in the amount of $21,018 had been accrued for Series B Preferred Stock special dividend as of December 31, 2011 and the $349,882 was accrued as a result of the NeoGenomics transaction in 2012.  These accruals resulted in the Company making the required payment to the Series B Preferred shareholders of approximately $370,900.
	During 2013, five Series B holders requested, and the Company complied with the Series B holders’ request to convert 8,512,675 Series B Preferred Stock to Common Stock.  The Company also paid the Series B holders who chose to convert, their portion of the accrued special dividend and accrued dividend.
	No dividend payment will be made if, after the payment of such dividend, the Company would not be able to pay its debts as they become due in the usual course of business, or the Company’s total assets would be less than the sum of its total liabilities plus the amount that would be needed, if the Company were to be dissolved, to satisfy the preferential rights upon the dissolution to shareholders whose preferential rights are superior to those receiving the dividend.
	Series C Preferred Stock
	In the fourth quarter of 2013, the Board of Directors authorized issuing up to 12,500,00 Series C Preferred Shares and the Company began to receive funding for the Series C Preferred Shares. As of December 31, 2013 the Company issued two million preferred shares at $0.08 for a total of $160,000. The Series C Preferred Shares feature $0.08 warrants and $0.08 contingency warrants. The contingency warrants will be issued only if the company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days.  The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days.  The warrants were valued at $0.025 each using the Black Scholes Method.
	The goal is to raise a maximum of $1,000,000 funds via this funding. This funding is anti-dilutive because the purchase price is significantly higher than the current 180-day average share price. The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.
	The Series C Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance.

INVESTMENT_IN_AVAILABLE_FOR_SA

INVESTMENT IN AVAILABLE FOR SALE SECURITIES	12 Months Ended
	Dec. 31, 2013
Available-For-Sale Securities [Abstract]	'
INVESTMENT IN AVAILABLE FOR SALE SECURITIES	'
	Note J – INVESTMENT IN AVAILABLE FOR SALE SECURITIES
	The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, as it relates to its shares held in NeoGenomics’ common stock that were acquired resulting from the NeoGenomics Master License Agreement executed on January 6, 2012. Management made the election for the fair value option related to this investment because it believes the fair value option for the NeoGenomics common stock provides a better measurement from which to compare financial statements from reporting period to reporting period. No other financial assets or liabilities are fair valued using the fair value option.
	The Company’s investment in NeoGenomics’ common stock is recorded on the accompanying balance sheets under the caption Investment in Available for Sale Securities. The carrying value of this investment on the date of acquisition approximated $1,945,000. The change in fair value from the prior period to December 31, 2013 is an unrecognized loss of $288,600 for the remaining 200,000 shares held and is classified as other expense under the caption Unrealized Loss on Available for Sale Securities in the accompanying statements of operations. The Company classifies its investment as an available for sale security presented as a trading security on the balance sheet and the fair value is considered a Level 1 investment in the fair value hierarchy. The December 31, 2013 fair value of the investment of $724,000 is for the remaining shares held and is calculated using the closing stock price of the NeoGenomics common stock at the end of the reporting period.
	During 2013, the Company sold 492,000 shares of NeoGenomics and received proceeds in the amount of $1,519,313. These transactions resulted in the Company recognizing a Realized Gain on the Sale of Available for Sale Securities in the accompanying statements of operations in the amount of $815,753 in the current period.
	As of December 31,2013 the Company held 200,000 shares of NeoGenomics stock as compared to 692,000 shares as of December 31, 2012.  The initial 1,360,000 shares were acquired in January 2012 as a result of the NeoGenomics Master License Agreement.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	Note K – SUBSEQUENT EVENTS
	None.

FINANCIAL_CONDITION_AND_GOING_

FINANCIAL CONDITION AND GOING CONCERN	12 Months Ended
	Dec. 31, 2013
Financial Condition and Going Concern [Abstract]	'
FINANCIAL CONDITION AND GOING CONCERN	'
	Note L – FINANCIAL CONDITION AND GOING CONCERN
	We have prepared our financial statements on a “going concern” basis, which presumes that we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future.
	Our ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing and successfully bringing our technologies to the market.  The outcome of these matters cannot be predicted at this time.  Our financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should we be unable to continue in business.
	If the going concern assumption was not appropriate for our financial statements then adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.  Such adjustments may be material.
	At December 31, 2013 we had $71,991 cash on hand along with its NeoGenomics Stock available for sale worth $724,000 and our current monthly cash expenses were approximately $50,000. As a result, the Company estimated cash will be depleted by the first quarter of 2015 if no additional capital raise was undertaken.
	The Company’s plan to have sufficient cash to support operations is comprised of selling its NeoGenomics Stock, generating revenue through its relationship with NeoGenomics, providing services related to those patents, and obtaining additional equity or debt financing.
	As a result the Company is focusing its efforts to secure funds via licensing activity or other forms of fund raising either in the debt or equity markets.  The Company has begun raising capital through the Series C Preferred Stock offering. The Company believes the Series C Preferred Stock offering, along with disciplined expense management, will allow the Company to maintain operations throughout 2015. In addition, the Company believes the NeoGenomics relationship will provide revenue the Company in 2015. While the Company believes these efforts will create a profitable future, there is no guarantee the Company will be successful in these efforts.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
USE OF ESTIMATES	'
	USE OF ESTIMATES
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period.  Accordingly, actual results could differ from those estimates.  Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the recoverability of the patents.
REVENUE RECOGNITION	'
	REVENUE RECOGNITION
	Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements.  These arrangements are generally governed by contracts that dictate responsibilities and payment terms.  The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled.  If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.
CASH AND CASH EQUIVALENTS	'
	CASH AND CASH EQUIVALENTS
	Cash and cash equivalents include cash and monies invested in overnight funds with financial institutions.
ACCOUNTS RECEIVABLE	'
	ACCOUNTS RECEIVABLE
	Trade accounts receivable for licensing fees and development services are recorded at net contract value based upon the written agreement with the customer. In certain cases, accounts receivable may include royalties’ receivable from customers based upon those customers estimated sales of the products or diagnostic tests containing patented processes and technologies. The Company considers amounts past due based on the related terms of the agreement and reviews its exposure to amounts receivable based upon collection history and specific customer credit analysis.  The Company provides an allowance for doubtful amounts if collectability is no longer reasonably assured.  As of December 31, 2013 and 2012, all amounts receivable are considered fully collectable and no allowance for doubtful accounts was recorded.
PROPERTY AND EQUIPMENT	'
	PROPERTY AND EQUIPMENT
	Property and equipment, which consists of office furniture, computer equipment and leasehold improvements, are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 10 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter.
PATENTS	'
	PATENTS
	Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued.  Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the capitalized costs to date in the period of abandonment or earlier if abandonment appears probable.  The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2013, the Company does not believe there has been any impairment of its intangible assets.
INVESTMENTS	'
	INVESTMENTS
	The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies, but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies.
INCOME TAXES	'
	INCOME TAXES
	The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled.
	In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such assets is made. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies.
STOCK-BASED COMPENSATION	'
	STOCK-BASED COMPENSATION
	Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
	Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model.  Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates.
	Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior.
	Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility.
	Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
RESEARCH AND DEVELOPMENT EXPENSE	'
	RESEARCH AND DEVELOPMENT EXPENSE
	The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. The R&D costs were $115,934 in 2013 and $127,648 in 2012.
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company’s financial instruments consist of cash, accounts receivable, accounts payable and accrued expenses.  The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note J for discussion regarding the valuation of the Company’s investment in available for sale securities.
NET LOSS PER SHARE	'
	NET LOSS PER SHARE
	Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss in all periods presented the calculation of diluted per share amounts would cause an anti-dilutive result and therefore is not presented. Potentially dilutive shares at December 31, 2013 and 2012 include options and warrants outstanding of 13,500,000 and 12,250,000, respectively.
CONCENTRATIONS OF CREDIT RISK	'
	CONCENTRATIONS OF CREDIT RISK
	The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account.  From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC.  Management believes the risk of loss of cash balances in excess of the insured limit to be low.
RECENT ACCOUNTING PRONOUNCEMENTS	'
	RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the FASB issued an amendment, which requires disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance is effective prospectively for annual and interim periods beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our financial results.

DEFERRED_REVENUE_Tables

DEFERRED REVENUE (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Revenue Disclosure [Abstract]	'
Schedule of expected future annual recognition of revenue	'
	2014	$	1,024,988
	2015		43,388
	2016		43,388
	2017		43,388
	2018		43,388
	Thereafter		18,076
	Total expected future annual amortization	$	1,216,616

PATENTS_Tables

PATENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of cost and accumulated amortization	'
		2013			2012
	Cost of Patents	$	3,985,794		$	3,985,794
	Accumulated Amortization		(2,519,290	)		(2,256,570	)
	Patents, Net of Amortization	$	1,466,504		$	1,729,224

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of deferred tax assets and liabilities	'
		2013			2012
	Net operating loss	$	7,682,814		$	6,979,391
	Deferred revenue		413,649			762,145
	Charitable contributions		510			1,088
	Depreciation and amortization		-			2,441
	Stock compensation		54,655			414,119
	Deferred tax asset		8,151,628			8,159,184
	Depreciation and amortization		(4,007	)		-
	Unrealized gain		(148,920	)		-
	Deferred tax liability		(152,927	)		-
	Net deferred tax asset		7,998,701			8,159,184
	Less valuation allowance		(7,998,701	)		(8,159,184	)
	Net deferred taxes	$	-		$	-
Schedule of income tax expense (Benefit)	'
	2013		2012
	Total expense (benefit) computed by:
	Applying the U.S. Federal statutory rate		(34.0	)%		(34.0	)%
	State income taxes, net of federal tax benefit		(3.0	)		(3.0	)
	Valuation allowance		37			37
	Effective tax rate (benefit)		-			-

STOCKBASED_COMPENSATION_AND_OT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of stock option and warrant information of the company	'
	Number of Warrants and Options Issued	2013			Weighted Average		2012			Weighted Average
					Exercise Price					Exercise Price
	Outstanding beginning of year		12,250,000		$	0.1		30,291,667		$	0.16
	Granted		17,750,000		$	0.04		1,000,000		$	0.05
	Exercised		-		$	-		(473,334	)	$	0.07
	Forfeited		(8,500,000	)	$	0.12		(3,000,000	)	$	0.12
	Expired un-exercised		(8,000,000	)	$	0.08		(15,568,333	)	$	0.21
	Outstanding end of the year		13,500,000		$	0.05		12,250,000		$	0.1
	Exercisable December 31		4,750,000		$	0.04		11,000,000		$	0.11
Schedule of combined stock option and warrant information of the company	'
	31-Dec-13
	Exercise Prices	Number			Weighted-		Number			Weighted
		Outstanding			Average		Exercisable			Average
					Remaining					Remaining
					Contractual					Contractual Life
					Life (years)					(years) of
										Exercisable
										Warrants
	$0.03		3,000,000			9.5		-			-
	$0.04		7,750,000			9.75		2,000,000			9.75
	$0.04		1,000,000			4		1,000,000			4
	$0.05		1,000,000			4		1,000,000			4
	$0.08		750,000			0.5		750,000			0.5
	Total		13,500,000					4,750,000
Schedule Of Stock-Based Compensation and Expense	'
		2013			2012
	Director’s option expenses	$	30,855		$	94,098
	Common stock issued for services		124,889			150,000
	Net Increase	$	155,744		$	244,098

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'
Estimated useful life of property and equipment	'3 to 10 years	'
Maximum ownership in equity investments in ventures	50.00%	'
Research and development costs	$115,934	$127,648
Potentially dilutive shares, options and warrants outstanding (in shares)	13,500,000	12,250,000
Cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation per account	$250,000	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 1) (Patents)	12 Months Ended
	Dec. 31, 2013
Patents	'
Finite-Lived Intangible Assets [Line Items]	'
Useful life of finite-lived intangible assets	'17 years

DEFERRED_REVENUE_Expected_futu

DEFERRED REVENUE - Expected future annual recognition of revenue (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Deferred Revenue Disclosure [Abstract]	'
2014	$1,024,988
2015	43,388
2016	43,388
2017	43,388
2018	43,388
Thereafter	18,076
Total expected future annual amortization	$1,216,616

DEFERRED_REVENUE_Detail_Textua

DEFERRED REVENUE (Detail Textuals) (USD $)	Dec. 31, 2013	Jan. 31, 2012	Mar. 31, 2010	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
		NeoGenomics Master License Agreement	NeoGenomics Master License Agreement	NeoGenomics Master License Agreement	NeoGenomics Master License Agreement	Underlying Patents	Underlying Patents	Underlying Patents	Underlying Patents
							NeoGenomics Master License Agreement	Minimum	Maximum
								NeoGenomics Master License Agreement	NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'
Deferred revenue received in cash	'	$2,944,800	$500,000	'	'	'	'	'	'
Period to recognize deferred revenue as income	'	'3 years	'	'	'	'	'	'	'
Deferred revenue recorded and recognized as income	'	'	'	2,944,800	500,000	'	'	'	'
Amount related to acceleration of revenue recognition from deferred revenue	'	'	'	457,088	'	'	'	'	'
Estimated remaining term of the underlying patents	'	'	'	'	'	'5 years 6 months	'8 years	'1 year	'7 years
Total unearned revenue	$1,216,616	'	'	'	'	'	'	'	'

PATENTS_Details

PATENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Cost of Patents	$3,985,794	$3,985,794
Accumulated Amortization	-2,519,290	-2,256,570
Patents, Net of Amortization	$1,466,504	$1,729,224

PATENTS_Detail_Textuals

PATENTS (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization charged to operations	$262,719	$262,719
Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization charged to operations	262,719	262,719
Estimated future amortization expense year 1	260,603	'
Estimated future amortization expense year 2	260,603	'
Estimated future amortization expense year 3	260,603	'
Estimated future amortization expense year 4	260,603	'
Estimated future amortization expense year 5	$260,603	'
Weighted average remaining amortization period	'5 years 6 months	'

INVESTMENT_Detail_Textuals_1

INVESTMENT (Detail Textuals 1) (USD $)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Mar. 27, 2007	Dec. 31, 2013	Dec. 31, 2012	Aug. 31, 2008	Dec. 31, 2010
		SVM Capital LLC	SVM Capital LLC	SVM Capital LLC	Smart Personalized Medicine, LLC	Smart Personalized Medicine, LLC	Smart Personalized Medicine, LLC	Smart Personalized Medicine, LLC
							License Agreement	Quest License and Development Agreement
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'	'	'
Percentage of membership interest	50.00%	'	'	45.00%	'	'	20.00%	50.00%
Carrying value of investment	'	$0	$0	'	$0	$0	'	'
Amount of initial investment	'	'	'	$5,000	'	'	'	'

LICENSE_FEES_EXPENSE_LUCENT_AG1

LICENSE FEES EXPENSE - LUCENT AGREEMENT (Detail Textuals) (Patent License Agreement, Lucent Technologies GRL Corporation, USD $)	1 Months Ended	12 Months Ended
	Sep. 26, 2004	Dec. 31, 2013	Dec. 31, 2012
Patent License Agreement | Lucent Technologies GRL Corporation	'	'	'
Agreement [Line Items]	'	'	'
Description of condition for royalty payment	'	'The Company agreed to pay royalty fees to Lucent in the amount of the greater of an annual fee of $10,000 or at the rate of five percent (5%) on each licensed product which is sold, leased, or put into use by the Company, until cumulative royalties equal $40,000 and at the rate of one percent (1%) subsequently.	'
Royalty, annual fee	$10,000	'	'
Annual fee rate	5.00%	'	'
Cumulative royalties	40,000	'	'
Cumulative royalties rate	1.00%	'	'
Royalty fees paid	'	$10,536	$13,237

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carry-forward	$7,682,814	$6,979,391
Deferred revenue	413,649	762,145
Charitable contributions	510	1,088
Depreciation and amortization	'	2,441
Stock compensation	54,655	414,119
Deferred tax asset	8,151,628	8,159,184
Depreciation and amortization	-4,007	'
Unrealized gain	-148,920	'
Deferred tax liability	-152,927	'
Net deferred tax asset	7,998,701	8,159,184
Less valuation allowance	-7,998,701	-8,159,184
Net deferred taxes	'	'

INCOME_TAXES_Details_1

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Applying the U.S. Federal statutory rate	-34.00%	-34.00%
State income taxes, net of federal tax benefit	-3.00%	-3.00%
Valuation allowance	37.00%	37.00%
Effective tax rate (benefit)	'	'

INCOME_TAXES_Details_Textuals

INCOME TAXES (Details Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Increase in the valuation allowance	$160,482
Net operating loss carry-forwards	$22,600,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	1 Months Ended	12 Months Ended
	Jul. 31, 2013	Dec. 31, 2013
Loss Contingencies [Line Items]	'	'
Area of office space given on lease	'	350
Base rent per month	'	$600
Settlement expense	'	50,000
Settlement agreement | Stephen Barnhill	'	'
Loss Contingencies [Line Items]	'	'
Amount paid for benefit of Mr. Barnhilland under settlement agreement	50,000	'
Settlement expense	'	$50,000

STOCKBASED_COMPENSATION_AND_OT1

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details) (Warrants and Options, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrants and Options	'	'
Number of Warrants and Options Issued	'	'
Outstanding beginning of year	12,250,000	30,291,667
Granted	17,750,000	1,000,000
Exercised	'	-473,334
Forfeited	-8,500,000	-3,000,000
Expired un-exercised	-8,000,000	-15,568,333
Outstanding end of the year	13,500,000	12,250,000
Exercisable December 31	4,750,000	11,000,000
Weighted Average Exercise Price	'	'
Outstanding beginning of year	$0.10	$0.16
Granted	$0.04	$0.05
Exercised	'	$0.07
Forfeited	$0.12	$0.12
Expired un-exercised	$0.08	$0.21
Outstanding end of the year	$0.05	$0.10
Exercisable December 31	$0.04	$0.11

STOCKBASED_COMPENSATION_AND_OT2

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number Outstanding	13,500,000
Number Exercisable	4,750,000
Stock Options and Warrants | $0.027	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.03
Number Outstanding	3,000,000
Weighted-Average Remaining Contractual Life (years)	'9 years 6 months
Number Exercisable	'
Stock Options and Warrants | $0.036	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.04
Number Outstanding	7,750,000
Weighted-Average Remaining Contractual Life (years)	'9 years 9 months
Number Exercisable	2,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'9 years 9 months
Stock Options and Warrants | $0.040	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.04
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	'4 years
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'4 years
Stock Options and Warrants | $0.050	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.05
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	'4 years
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'4 years
Stock Options and Warrants | $0.080	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.08
Number Outstanding	750,000
Weighted-Average Remaining Contractual Life (years)	'6 months
Number Exercisable	750,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'6 months

STOCKBASED_COMPENSATION_AND_OT3

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'	'
Stock-based compensation	$30,855	$94,098
Common stock issued for services	124,889	150,000
Net Increase	$155,744	$244,098

STOCKBASED_COMPENSATION_AND_OT4

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	$155,744	$244,098
Director option expenses	30,855	94,098
Common stock issued for service expenses related to employees and consultants	124,889	150,000
Stock Options and Warrants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation unrecognized for stock options and warrants	193,940	'
Average remaining vesting period for recognition of unrecognized expenses related to stock options and warrants	'2 years 6 months	'
Weighted average remaining life of outstanding warrants and options	'9 years 6 months	'
Aggregate intrinsic value of outstanding and exercisable options and warrants	$636,237	'

STOCKBASED_COMPENSATION_AND_OT5

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals 1) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

Dec. 31, 2013

Jul. 25, 2013

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2013

31-May-13

Jul. 25, 2013

Jul. 25, 2013

Jul. 25, 2013

Jul. 25, 2013

Oct. 21, 2013

Dec. 31, 2013

Jun. 30, 2013

Employment Agreement

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Common Shares

Mr. Norris

Mr. Sumio Takeichi

Mr. David Eckoff

Norman Mineta

Henry Kaplan

Kevin Kowbel

Eric Winger

Messrs Kaplan And Winger

William F Quirk

Employment Agreement

Consulting Agreement

Mr. Norris

Mr. Norris

Herbert Fritsche

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock issued as one-time bonus

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of schedule of options grant and vest

'

'

'

'

'

'

'

'

'

'

'

'

'These options will be granted and vest according to the following schedule: (i) 1,000,000 options were granted on December 18, 2012 at an exercise price of $0.05 and vest during the six months following the grant date, plus the potential to earn additional options if certain anniversary dates and other milestones were met. None of those milestones were met and therefore not awarded.

'

Number of option granted

'

'

'

1,500,000

1,500,000

1,500,000

1,500,000

1,500,000

1,500,000

1,500,000

'

1,500,000

1,000,000

1,000,000

Fair value of each stock option (in dollars per share)

'

$0.02

$0.02

'

'

'

$0.04

'

'

'

'

'

'

$0.03

Number of option vest or to be vested

'

'

'

'

'

'

'

'

'

'

250,000

250,000

'

'

Exercise price of each option granted (in dollars per share)

'

'

$0.03

'

'

'

$0.05

'

'

'

$0.03

$0.04

$0.05

$0.04

Method used for fair value assumptions

'

'Black-Scholes pricing model

'Black-Scholes pricing model

'

'

'

'Black-Scholes pricing model

'

'

'

'

'

'

'Black-Scholes pricing model

Dividend yield

'

0.00%

0.00%

'

'

'

0.00%

'

'

'

'

'

'

0.00%

Risk free interest rate

'

1.91%

1.97%

'

'

'

1.91%

'

'

'

'

'

'

1.91%

Expected life of option

'

'5 years

'5 years

'

'

'

'5 years

'

'

'

'

'

'

'5 years

Expected volatility rate

'

98.00%

96.00%

'

'

'

97.00%

'

'

'

'

'

'

97.00%

Aggregate value of stock options

'

$60,124

'

'

'

'

'

'

'

'

'

'

'

$29,454

Vesting period of option

'

'3 years

'3 years

'

'

'

'3 years

'

'

'

'

'

'6 months

'

STOCKBASED_COMPENSATION_AND_OT6

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals 2) (Stock Options, USD $)	1 Months Ended
	Oct. 21, 2013	Jul. 25, 2013	Feb. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period of option	'	'3 years	'3 years
Options Compensation cost not yet recognized	$203,931	'	'
Options Compensation cost recognition period	'3 years	'	'
Employees And Consultants	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of option granted to purchase common stock	6,000,000	'	'
Vesting period of option	'3 years	'	'
Exercise price of option	$0.04	'	'
Expiry date of option	21-Oct-23	'	'
Mark A. Moore	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of option granted to purchase common stock	1,000,000	'	'
Hong Zhang	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of option granted to purchase common stock	750,000	'	'

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDERS' EQUITY (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2009	Sep. 30, 2009
	Stockholder
Class of Stock [Line Items]	'	'	'	'	'
Dividend accrued on Series B preferred stock	308,724	'	'	'	'
Dividend accrued for Series B Preferred Stock	'	455,546	'	'	'
Series B Preferred Stock	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'
Series B Preferred Stock, shares authorized (in shares)	20,625,000	20,625,000	'	20,625,000	13,750,000
Number of series B preferred stock issued (in shares)	'	'	'	19,402,675	'
Amount of Series B Preferred Stock Issued	'	'	'	1,490,015	'
Dividend rate on Series B Preferred Stock	10.00%	'	'	'	'
Percentage of special dividend for Series B preferred stock	15.00%	'	'	'	'
Internal annual rate of return on Series B Preferred Stock	20.00%	'	'	'	'
Special dividend accrued on Series B preferred stock	'	349,882	21,018	'	'
Special dividends paid to the Series B holders	'	$370,900	'	'	'
Number of Series B preferred Stock holders who choose to convert their holdings	5	'	'	'	'
Number of Series B preferred Stock shares to be converted (in shares)	8,512,675	'	'	'	'

STOCKHOLDERS_EQUITY_Detail_Tex1

STOCKHOLDERS' EQUITY (Detail Textuals 1) (Series C Preferred Stock, USD $)	3 Months Ended
	Dec. 31, 2013
Series C Preferred Stock	'
Class Of Stock [Line Items]	'
Number of shares authorized to be issued	1,250,000
Preferred Stock, shares issued	2,000,000
Par value of preferred shares issued	$0.08
Value of preferred shares issued	$160,000
Preferred shares warrant feature per share	$0.08
Preferred shares contingency warrant feature per share	$0.08
Series C Preferred stock, contingency warrant exercise description	'The contingency warrants will be issued only if the company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days.  The holders must also exercise fifty percent of the warrants if the market price for the Company's common stock is $0.30 for a period of thirty consecutive calendar days.
Percentage of warrants exercise if market price for Company's common stock is $0.20	50.00%
Price per share for exercise of warrants, condition one	0.2
Number of days for common stock price at $0.20	'30 days
Percentage of warrants exercise if market price for Company's common stock is $0.30	50.00%
Price per share for exercise of warrants, condition two	0.3
Number of days for common stock price at $0.30	'30 days
Valuation method for warrants	'Black Scholes Method
Fair value of exercise price of warrants	$0.03
Maximum amount of fund raising	$1,000,000

INVESTMENT_IN_AVAILABLE_FOR_SA1

INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Number of shares sold during third and fourth quarters of 2012	252,557,310	233,773,144
Neo Genomics Laboratories Inc	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Unrecognized loss on available for sale securities	$288,600	'
Number of remaining shares held	200,000	'
Number of shares sold during third and fourth quarters of 2012	492,000	'
Amount of shares sold during third and fourth quarters of 2012	1,519,313	'
Realized gain on sale of available for sale securities	815,753	'
Number of shares of Neo Genomics stock held	200,000	692,000
Number of shares initially acquired	1,360,000	'
Carrying value | Neo Genomics Laboratories Inc	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available for sale securities	1,945,000	'
Fair value | Neo Genomics Laboratories Inc	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available for sale securities	$724,000	'

FINANCIAL_CONDITION_AND_GOING_1

FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Financial Condition and Going Concern [Abstract]	'	'	'
Cash	$71,991	$171,424	$890,326
Investment in NeoGenomics Stock available for sale	724,000	1,716,160	'
Monthly cash expenses	$50,000	'	'